Haifeng Cao, VP, Regulatory and External Affairs & PV
Daisy Zhou, Head of Preclinical and Translational Science
Susan Wu, Executive Director, Corporate Strategy and COO
Eric Wu, Director, Business Development
Qian Huang, Executive Director, Head of Clinical Operations
Clement Popovici, Executive Director, Head of International Clinical Operations
Dr. Min Wang Irwin is the co-founder and CEO of Reistone. She has 25 years of experiences in clinical development and medical affairs, working for top multinational pharma companies in the US, Canada and China.
Prior to Reistone, Dr. Min Irwin was formerly a venture partner at Qiming Venture Capital. During the early stages of her career, Dr. Irwin had led several global clinical trials, before taking up executive positions within Bayer, GlaxoSmithKline and Takeda as VP, head of clinical development and medical affairs in China and AP. She has built and led whole development teams of >200 people composed of clinical physicians, operation, project management, regulatory affairs, drug safety, and medical information as well medical affairs. Under Dr. Min Irwin leadership, over 20 new drugs and indications in China and Canada were successfully approved.
Dr. Min Irwin received her Medical degree and Master degree from the Third Military Medical University in China and Ph.D. in Clinical Biochemistry from University of Toronto.
Dr. Aik Goh joined Reistone in 2018 as the Chief Medical Officer. He has 18 years of experiences in clinical and pharmaceutical industry. Dr. Goh is also a UK General Medical Council (GMC) registered doctor.
Prior to joining Reistone, Dr. Goh worked in GSK for 10 years, taking on increasingly important roles in mid and late phase clinical development. He was first based in the London head office and subsequently moved to China 5 years ago. He has significant experience in global and China registration programs leading to NDA approvals. While in China, he led multiple medical function teams, including clinical research, medical affair and MSLs in Respiratory and Neuroscience TA.
Dr. Goh received his Bachelor of Medicine and Surgery degree from the University of Aberdeen, UK, and has subsequently received a Doctorate of Medicine degree from Aberdeen. His MD research focused on the association between gastrointestinal reflux disease and the etiology of esophageal adenocarcinoma. Dr. Goh is also a Member of the Royal College of Surgeons of Edinburgh and the Royal College of Surgeons and Physicians of Glasgow.
Mr. Haifeng Cao joined Reistone in 2018 as the VP, head of regulatory affairs, PV and external affairs. Mr. Haifeng Cao has 19 years experiences in regulatory affairs with several top multinational pharma in China.
Before joining Reistone, Haifeng worked in GSK and BI China as the head of regulatory affairs, where he made great contributions to build and lead the China regulatory affairs teams, develop fit-in purpose China development strategy for global innovative product and governed their execution. More than 20 new product approvals were obtained in Oncology, NS, Infectious, Derm, Diabetes, CV, Immunology, Respiratory and Vaccines etc. with Mr. Haifeng Cao’s strong leadership.
Haifeng holds a BS in Chemistry from JiLin University, a Master in Chemistry from Chinese Academy of Sciences and an MBA from Renmin University.
Daisy Zhou join Reistone and served as Head of Preclinical and Translational Science since Nov.2019. Daisy worked over 12 years in drug discovery in Pharmaceutical R&D, she has accumulated significant experience in autoimmune immune diseases and immune-oncology drug discovery and translational science.
Prior to joining Reistone Biopharma, Daisy served for GlaxoSmithKline, Zailab and Novartis and worked as project leader for several Biologics as well as small molecule projects.
Daisy obtained B.S. diploma in Medicine in Shanghai JiaoTong University, then Ph.D degree of Immunology in University of Brussels and Postdoc training in Institute for Medical Immunology.
Susan Wu has served as Executive Director, Corporate Strategy and COO since Oct 2019. Susan boasts over 12 years of experience in healthcare industry.
Before joining Reistone Biopharma, she worked in Prosnav Capital responsible for exploring oversea fund business in healthcare, med tech and TMT sectors in markets including Canada and Europe. Prior to that, Susan worked in GlaxoSmithKline for more than a decade in broad spectrum in both pharma and vaccine sectors including business development, sales management, marketing, pipeline development, portfolio strategy, scientific engagement and patient advocacy. Susan obtained B.S. diploma in chemistry, then M.S. in Chemometrics from Tongji University, and MBA degree from Cheung Kung Graduate School of Business.
Dr. Eric Wu joined Reistone in Dec. 2018 as the Director of Business Development. Dr. Wu brings more than 15 years of experience in business development and R&D in global pharma in the US and China.
Prior to joining Reistone, Dr. Wu led the international business development activities at Qilu Pharmaceuticals, where he was a key member responsible of executing BD strategies and establishing R&D capabilities in US. Before that, Dr. Wu worked in J&J for more than 6 years as a statistical lead in its pharmacogenomics group and was involved with new product FDA submissions in oncology and CNS. Dr. Wu also had more than 8 years research experiences in human genetics and published more than 30 peer reviewed articles.
Dr. Eric Wu holds a Ph.D. in Genetics from Texas A&M University, MS in Statistics from The University of Chicago and an MBA from New York University.
Qian Huang joined Reistone in 2019 as Executive Director, Head of Clinical Operations. Qian has about 15 years experiences in clinical development across therapeutic areas in oncology, cardiovascular, respiratory and infectious diseases.
Before joining Reistone, Qian has worked in MSD R&D as head of clinical project management where she built up and strengthened the clinical operation expertise and project management capacities for PhI-IV studies. And prior to that she worked in Roche as global studies leader to start the global study management presence and outreach across US and Asia pacific regions.
Qian holds a master degree in pharmacology from Medical school, Fudan University in China.
Clement Popovici joined Reistone in 2020 as Executive Director, Head of International Clinical Operations.
He has over 20 years of experience in the pharmaceutical industry focused in the Clinical Operations area.
Clement spent 18 years at Takeda Pharmaceuticals in various Clinical Operations roles of increasing responsibility across numerous therapeutic areas, lastly as Senior Director Clinical Operations of Neuroscience and Marketed Products. He has experience in providing global leadership in the planning and execution of clinical studies across all phases of development. Most recently prior to joining Reistone, Clement supported the Global Clinical Development team at Baxter Healthcare. His focus was on process improvements and systems, in addition to initiating activities for post-marketing clinical studies to enable compliance with the new requirements of the EU Medical Device Regulations.
Clement received his Masters in Biotechnology from Northwestern University and Bachelors in Chemistry from the University of Chicago.